

Supplemental Table 4: Change from baseline after 12 months (delta value, 12-month value minus baseline value) in the placebo and the vitamin D group according to DBP phenotypes

		DBP phenotypes					
		Gc1S/Gc1S	Gc1S/Gc1F	Gc1S/Gc2	Gc1F/Gc1F	Gc1F/Gc2	Gc2/Gc2
Number of subjects (placebo / vitamin D)		72 / 76	66 / 58	61 / 56	11 / 9	17 / 22	9 / 15
Serum delta DBP (µmol/L)	Placebo	- 0.2 ± 0.5	- 0.3 ± 0.6	- 0.2 ± 0.5	- 0.4 ± 0.6	- 0.2 ± 1.0	- 0.2 ± 0.6
	Vitamin D	- 0.2 ± 0.6	- 0.1 ± 0.5	- 0.2 ± 0.5	- 0.1 ± 0.6	- 0.3 ± 0.6	- 0.2 ± 0.4
Serum delta total 25(OH)D (nmol/L)	Placebo	2.6 ± 17.6	3.1 ± 19.1	2.6 ± 14.8	9.9 ± 14.7	6.8 ± 17.7	7.1 ± 11.4
	Vitamin D	53.6 ± 25.8	45.1 ± 24.6	38.8 ± 20.8	55.7 ± 13.6	36.6 ± 22.6	42.1 ± 16.2
Serum delta calculated free 25(OH)D (pmol/L)	Placebo	2.4 ± 5.7	2.5 ± 6.6	1.7 ± 4.9	4.8 ± 5.6	3.3 ± 6.2	4.3 ± 6.3
	Vitamin D	20.5 ± 9.5	16.3 ± 9.6	15.1 ± 7.8	19.4 ± 5.9	13.7 ± 7.6	18.4 ± 5.9
Serum delta directly measured free 25(OH)D (pmol/L)	Placebo	- 0.4 ± 3.3	- 0.7 ± 3.8	- 1.0 ± 2.7	0.8 ± 3.6	0.5 ± 3.5	0.2 ± 3.4
	Vitamin D	10.2 ± 5.3	8.5 ± 4.6	7.6 ± 3.7	10.6 ± 4.0	7.2 ± 5.4	10.2 ± 3.8

DBP, vitamin D binding protein; 25(OH)D, 25-hydroxyvitamin D